{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-22-000025","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.891595+00:00","generated_at":"2026-06-24T02:55:41.114275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pliant Therapeutics Q2 net loss $29.5M; pro-forma cash $379.8M after $215.7M offering","bullets":["Net loss of $29.5M in Q2 2022 vs $22.8M in prior-year quarter; R&D expenses $26.3M (up from $19.2M).","Pro-forma cash, cash equivalents and short-term investments of $379.8M as of June 30, 2022.","PLN-74809 INTEGRIS-IPF Phase 2a met primary endpoint; dose-dependent effects on FVC and QLF observed.","FDA Fast Track designation for PLN-74809 in PSC; topline data from INTEGRIS-PSC expected H1 2023.","Received $4.0M milestone from Novartis collaboration; loan facility with Oxford Finance provides up to $100M."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-22-000025","json":"https://secwatch.observer/filing/0001746473-22-000025.json","markdown":"https://secwatch.observer/filing/0001746473-22-000025.md","text":"https://secwatch.observer/filing/0001746473-22-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647322000025/0001746473-22-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647322000025/plrx-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:55:41.114275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}